Lactylated nijmegen breakage syndrome 1 protein and uses thereof
AssigneeThe Seventh Affiliated Hospital, Sun Yat-Sen University
InventorsChanghua Zhang, Hengxing Chen
Life of this patent
Estimating the term…
Abstract
Disclosed are a lactylated NBS1 protein and uses thereof. A lactylation site in this application is lysine at position 388 of NBS1 protein. Lactylation at K388 site of the NBS1 protein activates the DNA repair pathway and has multiple functions, including promoting radiotherapy and chemotherapy resistance in tumor cells and enhancing homologous recombination in DNA repair. By targeted inhibition of the lactylated NBS1 protein, tumor resistance to radiotherapy or chemotherapy can be reversed, providing a potential target for reversing tumor resistance to radiotherapy or chemotherapy.
Claims19
A kit for predicting efficacy of radiotherapy or chemotherapy for a tumor, comprising a reagent for detecting a lactylation level of Nijmegen breakage syndrome 1 (NBS1) protein, wherein a lactylation site is lysine at position 388 of the NBS1 protein.
A pharmaceutical composition for reversing tumor resistance to radiotherapy or chemotherapy, comprising an agent that specifically inhibits lactylation of NBS1 protein and a pharmaceutically acceptable carrier.
A gastric cancer cell line AGS, comprising in its genome a mutant NBS1 gene, wherein the mutant NBS1 gene comprises a mutation when compared to wild-type NBS1 gene, wherein the mutation changes the codon for lysine at position 388 of a protein encoded by the wild-type NBS1 gene to a codon for an amino acid that cannot be lactylated.
Dependencies are inferred from the claim text.